@prefix this: <http://bio2rdf.org/drugbank:DB05024_nanopub.RA8CVNjeOLfhSfThQMX3Il0QGFz3H1X9EiMtDuDtxY-dI> .
@prefix sub: <http://bio2rdf.org/drugbank:DB05024_nanopub.RA8CVNjeOLfhSfThQMX3Il0QGFz3H1X9EiMtDuDtxY-dI#> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix pav: <http://purl.org/pav/> .
@prefix orcid: <http://orcid.org/> .
@prefix codebase: <https://github.com/tkuhn/bio2rdf2nanopub> .
@prefix version: <https://github.com/tkuhn/bio2rdf2nanopub/tree/eda7951a5f6c622c5d2132f50c3093138484a349> .
@prefix instance: <https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB> .
@prefix process: <https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB.7720f136-841b-4851-a6e4-ad20a409a475> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix v: <http://bio2rdf.org/bio2rdf_vocabulary:> .
@prefix d: <http://bio2rdf.org/drugbank:> .
@prefix dv: <http://bio2rdf.org/drugbank_vocabulary:> .
@prefix dr: <http://bio2rdf.org/drugbank_resource:> .
@prefix dcat: <http://www.w3.org/ns/dcat#> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:publicationInfo;
    a np:Nanopublication .
}

sub:assertion {
  d:DB05024 v:identifier "DB05024";
    v:namespace "drugbank";
    v:uri "http://bio2rdf.org/drugbank:DB05024";
    v:x-identifiers.org <http://identifiers.org/drugbank/DB05024>;
    dv:drugbank-id "DB05024";
    dv:x-cas <http://bio2rdf.org/cas:>;
    dct:description "CTA018 is a member of a new class of vitamin D analogues with a dual mechanism of action, called Vitamin D Signal Amplifiers. This proprietary new drug is both a potent inhibitor of CYP24 (the enzyme responsible for the breakdown of vitamin D) and a potent activator of vitamin D signaling pathways. CTA018 will be the first drug with this novel dual mechanism of action to enter clinical development. Preclinical studies have shown that CTA018 inhibits the proliferation of rapidly dividing cells such as human epidermal keratinocytes (skin cells) and is also effective in inhibiting pro-inflammatory cytokine secretion which may be involved in the etiology of psoriasis. Cytochroma anticipates that CTA018 will be more potent than currently marketed vitamin D analogues such as calcitriol and calcipotriol and it is expected to have a greater safety index."@en;
    dct:identifier "drugbank:DB05024";
    dct:title "CTA018"@en;
    a dv:Drug;
    rdfs:label "CTA018 [drugbank:DB05024]"@en;
    rdfs:seeAlso <http://www.drugbank.ca/drugs/DB05024> .
}

sub:provenance {
  sub:assertion prov:wasDerivedFrom <http://download.bio2rdf.org/release/3/drugbank/drugbank.nq.gz> .
  
  dr:bio2rdf.dataset.drugbank.R3 dcat:distribution <http://download.bio2rdf.org/release/3/drugbank/drugbank.nq.gz> .
  
  <http://download.bio2rdf.org/release/3/drugbank/drugbank.nq.gz> dct:created "2015-01-09T17:00:50-05:00"^^xsd:dateTime;
    prov:wasDerivedFrom <http://www.drugbank.ca/system/downloads/current/drugbank.xml.zip#retrieved-on:2014-11-12T07:57:03-05:00> .
  
  <http://www.drugbank.ca/system/downloads/current/drugbank.xml.zip#retrieved-on:2014-11-12T07:57:03-05:00>
    pav:retrievedOn "2014-11-12T07:57:03-05:00"^^xsd:dateTime;
    prov:wasDerivedFrom <http://www.drugbank.ca/system/downloads/current/drugbank.xml.zip> .
  
  <http://www.drugbank.ca/system/downloads/current/drugbank.xml.zip> prov:wasAttributedTo
      <http://drugbank.ca> .
}

sub:publicationInfo {
  sub:signature.MCwCFAefF_heAjxE npx:hasPublicKey "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";
    npx:hasSignature "MCwCFAefF/heAjxEE2b+TSJzzge0aF4lAhQzU5Qsu1S2EsJ+5i/bRM1LZMR4yA==";
    npx:signedBy instance: .
  
  this: dct:created "2018-03-30T11:11:03.473+02:00"^^xsd:dateTime;
    dct:license <https://creativecommons.org/licenses/by-nc/4.0/>;
    npx:hasSignatureElement sub:signature.MCwCFAefF_heAjxE;
    prov:wasGeneratedBy process: .
  
  instance: prov:specializationOf codebase:;
    prov:wasAttributedTo orcid:0000-0002-1267-0234 .
  
  process: dct:identifier "7720f136-841b-4851-a6e4-ad20a409a475";
    prov:used version:;
    prov:wasAssociatedWith instance:;
    prov:wasStartedBy orcid:0000-0002-1267-0234 .
  
  version: dct:isVersionOf codebase:;
    pav:version "eda7951a5f6c622c5d2132f50c3093138484a349";
    prov:wasAttributedTo orcid:0000-0002-1267-0234 .
}